Dibromoacetic acid is a colorless to pale yellow liquid with a pungent odor. It is a strong acid and is corrosive to skin and eyes. It is soluble in water, ethanol, and ether. Dibromoacetic acid is used as a reagent in organic synthesis and as a catalyst in some industrial processes. It is also used in the production of pharmaceuticals and pesticides. Dibromoacetic acid is a potent inhibitor of the enzyme carbonic anhydrase. It is also known to have antibacterial and antifungal properties. Dibromoacetic acid is a halogenated carboxylic acid. It is a potent inhibitor of carbonic anhydrase, an enzyme that plays a role in the regulation of pH and carbon dioxide levels in the body. Dibromoacetic acid is a strong acid and is corrosive to skin and eyes. It is a volatile compound and should be handled with caution.'
dibromoacetic acid : A monocarboxylic acid that is acetic acid in which two of the methyl hydrogens are replaced by bromo groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 12433 |
CHEMBL ID | 449362 |
CHEBI ID | 90124 |
SCHEMBL ID | 137199 |
MeSH ID | M0234634 |
Synonym |
---|
hsdb 7622 |
acetic acid, 2,2-dibromo- |
7fuw62yy5l , |
unii-7fuw62yy5l |
dibromoacetic acid |
acetic acid, dibromo- |
inchi=1/c2h2br2o2/c3-1(4)2(5)6/h1h,(h,5,6 |
631-64-1 |
NCGC00090913-01 |
einecs 211-165-5 |
ccris 7636 |
dibromoacetate |
dibromoacetic acid, analytical standard |
dibromoacetic acid, 97% |
2,2-dibromoacetic acid |
MLS001065597 |
smr000568475 |
chebi:90124 , |
CHEMBL449362 |
AKOS000119767 |
NCGC00090913-02 |
LMFA01090076 |
dbaa |
2,2-dibromoethanoic acid |
C20123 |
cas-631-64-1 |
dtxcid203815 |
tox21_303291 |
dtxsid1023815 , |
NCGC00257152-01 |
tox21_202297 |
NCGC00259846-01 |
10024-50-7 |
FT-0632681 |
SCHEMBL137199 |
dibromoacetic acid [hsdb] |
dibromoacetic acid [iarc] |
dibromoethanoic acid |
dibromoacetic acid 1000 microg/ml in methyl-tert-butyl ether |
dibromoaceticacid |
Q18533477 |
s29 - haloacetic acids |
Dibromoacetic acid (DBA) is a disinfection by-product commonly found in drinking water as a result of chlorination/ ozonation processes. It could cause many adverse effects in test animals.
Excerpt | Reference | Relevance |
---|---|---|
"An evaluation of potential adverse human health effects of disinfection byproducts requires study of both cancer and noncancer endpoints; however, no studies have evaluated the neurotoxic potential of a common haloacetic acid, dibromoacetic acid (DBA)." | ( Neurotoxicity produced by dibromoacetic acid in drinking water of rats. Butt, MT; Jortner, BS; Levine, AB; McDaniel, KL; Moser, VC; Phillips, PM; Sills, RC, 2004) | 0.81 |
" We have previously shown that the haloacetic acids (HAs), dichloro (DCA), dibromo (DBA) and bromochloro (BCA) acetic acid are developmentally toxic in mouse whole embryo culture." | ( Developmental toxicity of mixtures: the water disinfection by-products dichloro-, dibromo- and bromochloro acetic acid in rat embryo culture. Andrews, JE; Hunter, ES; Klinefelter, GR; Mole, LM; Nichols, HP; Schmid, JE, 2004) | 0.32 |
" Toxic effects of DBA in the prechronic studies were detected in the liver (hepatocellular cytoplasmic vacuolization in rats and mice) and testes (delayed spermiation and atypical residual bodies in male rats and mice, and atrophy of the germinal epithelium in rats)." | ( Toxicity and carcinogenicity of the water disinfection byproduct, dibromoacetic acid, in rats and mice. Foster, PM; Kissling, GE; Melnick, RL; Nyska, A; Roycroft, JH, 2007) | 0.58 |
" To evaluate its potential adverse health effects, the immunotoxicological effects of DBA on the thymus and spleen of BALB/c mice were investigated." | ( Subacute oral exposure to dibromoacetic acid induced immunotoxicity and apoptosis in the spleen and thymus of the mice. Dong, Y; Gao, S; Li, B; Wang, Y; Zhang, P, 2008) | 0.65 |
" The role of gastrointestinal degradation in the toxic effects of DBPs still needs further investigation." | ( Gastrointestinal Degradation and Toxicity of Disinfection Byproducts in Drinking Water Using Hu, B; Li, D; Wang, P; Yin, J; Zheng, T, 2023) | 0.91 |
Excerpt | Reference | Relevance |
---|---|---|
" Exposure to HAAs is influenced by consumption patterns and diet of individuals thus their bioavailability is an important parameter to the overall toxicity." | ( In vitro bioacessibility and transport across Caco-2 monolayers of haloacetic acids in drinking water. Faria, MA; Ferreira, IMPLVO; Mansilha, C; Melo, A; Pinto, E, 2016) | 0.43 |
Role | Description |
---|---|
marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
apoptosis inducer | Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. |
geroprotector | Any compound that supports healthy aging, slows the biological aging process, or extends lifespan. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
monocarboxylic acid | An oxoacid containing a single carboxy group. |
2-bromocarboxylic acid | Any carboxylic acid in which the carbon bearing the carboxy group is substituted by a bromine. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 11.2202 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 35.4813 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 26.4577 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 6.8590 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 44.6684 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 0.6181 | 0.0010 | 22.6508 | 76.6163 | AID1224893 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 16.9036 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID588533 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 61.1306 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 28.1838 | 0.0237 | 23.2282 | 63.5986 | AID588543 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 5.0289 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID384212 | Mutagenic activity in Salmonella Typhimurium TA100 assessed as logarithm of his+ revertant number increasing activity by amens test | 2008 | Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10 | Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (1.79) | 18.7374 |
1990's | 7 (12.50) | 18.2507 |
2000's | 26 (46.43) | 29.6817 |
2010's | 19 (33.93) | 24.3611 |
2020's | 3 (5.36) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.57) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (1.43%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 69 (98.57%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |